The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

New Oral Antiplatelet Agents

최근 개발된 항혈소판제제

  • Kang, Min-Kyu (Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Chang, Kiyuk (Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • 강민규 (가톨릭대학교 의과대학 내과학교실) ;
  • 장기육 (가톨릭대학교 의과대학 내과학교실)
  • Published : 2013.07.01
⟨ Previous Next ⟩

Abstract

Antiplatelet agents play an essential role in the treatment of acute coronary syndrome (ACS). Aspirin and thienopyridines comprise the major classes of antiplatelet therapies demonstrated to be of benefit in the treatment of ACS. Thienopyridines are a class of drugs that function via inhibition of the adenosine diphosphate (ADP) $P2Y_{12}$ platelet receptors. While clopidogrel remains in extensive use in clinical practice, it cannot meet the needs in many clinical conditions because of its pharmacological limitations. In recent years, newly developed $P2Y_{12}$ antagonists, such as prasugrel and ticagrelor, have proven to be of higher efficacy and less resistance. As a third generation thienopyridine, prasugrel exerts a much more rapid and consistent inhibitory effect on platelet aggregation than clopidogrel. Treatment with ticagrelor, nonthienopyridine oral antiplatelet drug, significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding as compared with clopidogrel. The present review aims to discuss the current knowledge on the safety and efficacy of new oral antiplatelet agents including prasugrel and ticagrelor.

Keywords

References

  1. Steiner JB, Wu Z, Ren J. Ticagrelor: positive, negative and misunderstood properties as a new antiplatelet agent. Clin Exp Pharmacol Physiol 2013;40:398-403. https://doi.org/10.1111/1440-1681.12097
  2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. https://doi.org/10.1056/NEJMoa010746
  3. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175. https://doi.org/10.1161/01.CIR.0000130846.46168.03
  4. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015. https://doi.org/10.1056/NEJMoa0706482
  5. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057. https://doi.org/10.1056/NEJMoa0904327
  6. Wiviott SD, Antman EM, Braunwald E. Prasugrel. Circulation 2010;122:394-403. https://doi.org/10.1161/CIRCULATIONAHA.109.921502
  7. Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007;50:555-562. https://doi.org/10.1097/FJC.0b013e3181492209
  8. Sardella G, Calcagno S, Mancone M, et al. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial. Circ Cardiovasc Interv 2012;5:698-704. https://doi.org/10.1161/CIRCINTERVENTIONS.112.972463
  9. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-731. https://doi.org/10.1016/S0140-6736(09)60441-4
  10. Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626-1636. https://doi.org/10.1161/CIRCULATIONAHA.108.791061
  11. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITONTIMI 38 trial: a pharmacogenetic analysis. Lancet 2010; 376:1312-1319. https://doi.org/10.1016/S0140-6736(10)61273-1
  12. Schomig A. Ticagrelor: is there need for a new player in the antiplatelet-therapy field? N Engl J Med 2009;361:1108- 1111. https://doi.org/10.1056/NEJMe0906549
  13. Dinicolantonio JJ, Serebruany VL. Exploring the ticagrelorstatin interplay in the PLATO trial. Cardiology 2013;124: 105-107. https://doi.org/10.1159/000346151
  14. Teng R, Butler K. A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers. Eur J Clin Pharmacol 2013 Jun 9 [Epub]. http://dx.doi.org/10.1007/ s00228-013-1543-3.
  15. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/ OFFSET Study. Circulation 2009;120:2577-2585. https://doi.org/10.1161/CIRCULATIONAHA.109.912550
  16. James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011;342:d3527. https://doi.org/10.1136/bmj.d3527
  17. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010;122:2131-2141. https://doi.org/10.1161/CIRCULATIONAHA.109.927582
  18. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010;31: 3006-3016. https://doi.org/10.1093/eurheartj/ehq325
  19. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 2010;122:1056-1067. https://doi.org/10.1161/CIRCULATIONAHA.109.933796
  20. Nilsen DW. Potential Benefits of Ticagrelor beyond Platelet Inhibition. Cardiology 2013;125:31-33. https://doi.org/10.1159/000350358
  21. Van Giezen JJ, Sidaway J, Glaves P, Kirk I, Bjorkman JA. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2012;17:164-172. https://doi.org/10.1177/1074248411410883
  22. Ohman J, Kudira R, Albinsson S, Olde B, Erlinge D. Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochem Biophys Res Commun 2012;418:754-758. https://doi.org/10.1016/j.bbrc.2012.01.093
  23. Serebruany VL. Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial? Am Heart J 2011;161:1-4. https://doi.org/10.1016/j.ahj.2010.09.017
  24. Grzesk G, Kozinski M, Navarese EP, et al. Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats. Thromb Res 2012;130:65-69. https://doi.org/10.1016/j.thromres.2011.12.029
  25. Serebruany VL. Viewpoint: reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel. Thromb Haemost 2012;108:1024-1027. https://doi.org/10.1160/TH12-03-0180

Cited by

  1. A Case of Ticagrelor Rescue Therapy in a Patient with Subacute Stent Thrombosis vol.87, pp.5, 2014, https://doi.org/10.3904/kjm.2014.87.5.598
  2. Simultaneous Multivessel Acute Stent Thrombosis in a Patient with Gastrointestinal Bleeding vol.90, pp.4, 2013, https://doi.org/10.3904/kjm.2016.90.4.322